Amakem Therapeutics, a clinical stage ophthalmology company, today presented top-line clinical results for its lead drug candidate, AMA0076 for the treatment of glaucoma, at the Ophthalmology Innovation Summit (OIS) at the 2013 Annual Meeting of the American Academy of Ophthalmology.